Abstract: Cannabis preparations as recreational drugs are the most widely used illicit drugs in the world. Although cannabis derivatives produce clear subjective motivational responses in humans leading to drug-seeking behavior and in a specific proportion in repeated drug use, the reinforcing/rewarding attributes of these subjective effects are difficult to define in experimental animals. This led to the notion of cannabinoids being considered as "atypical" or "anomalous" drugs of abuse. To this end, our knowledge and understanding of the way cannabis and its main psychoactive constituent, 9 -tetrahydrocannabinol ( 9 -THC), act in the central nervous system to exert their reinforcing/rewarding effects is far from complete. The aim of the present article is to review from a preclinical perspective the current status of what is known about the behavioral pharmacology of cannabinoids including the recently identified cannabinoid neurotransmission modifiers with a particular emphasis on their motivational/reinforcing and dependence-producing properties. We conclude that cannabinoids exhibit reinforcing/rewarding properties in experimental animals mostly under particular experimental conditions, which is not the case for other drugs of abuse, such as opiates, psychostimulants, alcohol and nicotine. The paper will discuss these findings critically and also point to open questions that should be addressed in the future in order to improve our understanding of these specific actions of cannabinoids that will also impact drug discovery and development efforts of related compounds as therapeutics in the clinic.
INTRODUCTION
Cannabis derivatives are the most widely used illegal drugs in the world. The popularity of cannabis as a recreational drug is due to its ability to alter sensory processing as well as producing clear subjective motivational responses accompanied with a sense of mild euphoria and well-being. Indeed, this elation along with the sense of relaxation produced by cannabis, are among the most cited subjective psychotropic properties of the drug [1] . It has been suggested that in a proportion of regular users, these effects lead to drug-seeking behavior and repeated drug use [2] [3] [4] .
On the other hand, the ability of cannabis preparations to cause a variety of medicinal effects unrelated to its psychotropic effects has been recognized for more than 3000 years now [5] . The last years in many countries, public debate has focused on the possible legalization of cannabis and 9 -THC for therapeutic uses. Because the largest impediment to the development of therapeutic cannabinoid medications is the occurrence of euphoric side effects, which may lead to their abuse in humans, understanding the mechanisms through which these actions occur as well as their neuronal substrate may be essential to developing rational approaches to cannabinoid medication development. In spite of the well established abuse properties of cannabis preparations in humans, knowledge about the abuse liability of 9 -THC and other cannabinoid analogs in experimental animals is still limited, and undoubtedly this issue remains controversial. Consequently, our understanding of the way marijuana and its main psychoactive constituent, 9 -THC, act to exert their pleasurable effects in humans is far from complete.
In this review, evidence on the actions of cannabis, its main psychoactive ingredient 9 -THC, and more potent synthetic analogs and cannabinoid neurotransmission modifiers on brain reward circuitry will be provided and the possible underlying mechanisms will be discussed.
CANNABINOIDS AND THE ENDOCANNABINOID SYSTEM
Herbal cannabis contains over 400 compounds including over 60 terpeno-phenols, unique to the plant of cannabis, known as plant cannabinoids. One of these constituents, 9 -THC, has been the object of intense investigation [6, 7] , as it is, by far, the major psychoactive constituent of the plant. From the other plant cannabinoids, cannabidiol, a nonpsychoactive ingredient, has also been widely investigated as it exhibits interesting anti-inflammatory, anti-schizophrenic and antiepileptic actions [8] . The pharmacology and the behavioral actions of other plant cannabinoids are largely unknown. 9 -THC and other cannabinoids are highly lipophilic and were originally thought to act by simple diffusion through cell membranes, resulting in relatively non-selective disruption of neurotransmission [9] ; the last years, however, our knowledge about the cannabinoid system has increased enormously [5] . During the past decade, two cannabinoid receptors, named CB 1 [10] and CB 2 [11] , were cloned and their distribution and transduction pathways were described [12] . The CB 1 receptor is highly expressed in the central nervous system whereas the CB 2 receptor is primarily found in cells of the immune system [13] . However, recently the CB 2 receptor has also been located in specific brain regions [14, 15] . In addition to the CB 1 and CB 2 receptors, pharmacological evidence has been accumulating over the years to support the existence of more cannabinoid receptors [16] .
The presence of cannabinoid receptors in mammalians suggested the existence of endogenous ligands that bind and affect the function of these receptors. In 1992, the first endogenous ligand for these receptors, named anandamide (Narachidonoyl ethanolamide or AEA), was isolated [17] . Anandamide could be synthesized by neurons upon stimulation and it mimicked many biochemical, pharmacological and behavioral properties of cannabinoids [18, 19] . Three years after the discovery of anadamide, another endogenous ligand for the cannabinoid receptor, named 2-arachidonoyl glycerol (2-AG), was identified [20] . More recently, other molecules with cannabinoid receptor binding activity termed 2-arachidonoyl glyceryl ether (noladine ether), O-arachidonoyl ethanolamine (virodhamine) , and N-arachidonoyldopamine (NADA) have been discovered (for a recent review, see [21] ) and their physiological actions remain to be elucidated. Endogenous cannabinoids are produced from membrane-associated precursors and exert their neurochemical actions by binding and stimulating cannabinoid and vanilloid receptors [22] . Their concentrations are regulated in a strict manner through a reuptake process into cells and a rapid enzymatic inactivation [23, 24] .
The cannabinoid receptors, the endocannabinoids, the proteins that synthesize endocannabinoids and the proteins of the inactivation process together constitute what is now referred to as the "endocannabinoid system". This system modulates various physiological functions not only in the central nervous system but also in the autonomic nervous system, and in the gastrointestinal, the endocrine, the reproductive and the immune systems, as well as in the circulation [19] .
The development of potent and selective agonists and antagonists for the cannabinoid receptors or agents that block the reuptake or degradation of endocannabinoids has played a major role in the recent advances obtained in behavioral and pharmacological research of the cannabinoid system [25, 26] . Genetically modified mice have also been used as research tools to study the behavioral and pharmacological actions of cannabinoids (reviewed by [27, 28] ).
PHARMACOLOGICAL AND MOLECULAR TOOLS TO STUDY ENDOCANNABINOID NEUROTRANS-MISSION
The discovery of the cannabinoid receptors, the endocannabinoid ligands and associated enzymes which are responsible for their metabolism and deactivation has generated a great interest in developing novel cannabinoid therapeutic drugs. Many of them have been used extensively as pharmacological tools to study endocannabinoid neurotransmission and pharmacology. Currently, five major classes of cannabinoid analogues have been identified based on chemical structure [26, [29] [30] [31] .
Classical cannabinoids are tricyclic terpenoid derivatives bearing a benzopyran moiety. This group includes cannabisderived compounds (phytocannabinoids) and synthetic analogues. The major phytocannabinoids included in this group are 9 -THC, 8 -THC and cannabinol. From the synthetic analogues notable examples are the non-selective CB 1/ CB 2 receptor agonists, 11-hydroxy- 8 -THC-dimethylheptyl (HU-210), levonantradol, nabilone, AMG-3 and the selective CB 2 receptor agonists L-759633, L-759656 and JWH-133.
Non-classical cannabinoids consist of bicyclic and tricyclic analogues of 9 -THC lacking the pyran ring of classical cannabinoids. Notable examples include the potent nonselective CB 1/ CB 2 receptor agonists CP-55,940, CP-47,497, CP-55,244 and the selective CB 2 receptor agonist HU-308. [ 3 H]CP-55,940 was the key compound that led to the discovery of the CB 1 receptor [32] .
The class of aminoalkylindoles has a completely different structure from the other cannabinoids. They also differ in their lipophilicity (they are considerable less lipophilic) as well as in the way they activate cannabinoid receptors [33] . The most widely investigated compound from the aminoalkylindoles is the potent CB 1/ CB 2 receptor agonist WIN55,212-2. This compound has high stereoselectivity and slight preference for the CB 2 receptor. Other compounds of this class include the potent and selective CB 2 receptor agonist AM1241 and the selective CB 2 receptor antagonist AM630.
The eicosanoid group consists of cannabinoid receptor agonists that have markedly different structures both from aminoalkylindoles and from classical and non-classical cannabinoids. Notable members of this group are the endocannabinoids, anandamide, 2-AG, virodhamine, noladin ether and several synthetic analogues of anandamide, including R-(+)-methanandamide, arachidonyl-2'-chloroethylamide (A CEA), and arachidonylcyclopropylamide (ACPA).
The fifth class of 1,5 biarylpyrazoles includes cannabinoid-related compounds that act as cannabinoid receptor antagonists. SR141716A (rimonabant) was developed at Sanofi as the first CB 1 receptor antagonist and has since been used extensively as pharmacological tool in many studies. This compound shows selectivity for the CB 1 receptor and has often been reported to act as an inverse agonist rather than a neutral antagonist [34] . The follow-on synthesis of AM251 with a selectivity for the CB 1 receptor presented researchers with a similarly potent antagonist/inverse agonist. SR144528 was also developed at Sanofi as a CB 2 receptor antagonist.
The finding that the actions of anandamide and 2-arachidonoyl glycerol are terminated by cellular uptake and intracellular enzymatic hydrolysis has been followed by the development of several drugs that inhibit these processes [35, 36] . Several of these drugs have been used as pharmacological tools in animal experiments aimed at elucidating the pathophysiological roles of endocannabinoids. Important members of this group are the FAAH inhibitors PMSF, palmitylsulphonyl fluoride (AM374), stearylsulphonyl fluoride (AM381), O-1887, URB-532 and URB-597. Among the anandamide transport inhibitors, AM-404 is the most extensively studied. Other compounds of this group, with a more These seemingly contrasting results could be attributed to differences in the pharmacological properties and the dose range of the tested compounds, the strain of the animals used and the methods followed. For example, Lepore and colleagues [44] found the most pronounced action of 9 -THC in Lewis rats, compared to Sprague-Dawley rats in which the effect was marginal, whereas in the Fisher strain of rats there was no effect. The same group in their previous studies also used Lewis rats, which in general appear to be more sensitive and vulnerable to the effects of addictive drugs [41, 42] .
Furthermore, it should be noted that the rewardfacilitating effects of 9 -THC in the above-mentioned studies are much less pronounced than those shown with typical drugs of abuse, such as morphine, cocaine, amphetamine, MDMA or nicotine [48] [49] [50] [51] . These later drugs can reliably shift the rate-frequency function to the left by between 0.2 and 0.5 log units. However in the study by Lepore et al. [44] , 9 -THC could only shift the rate-frequency function to the left by approximately 0.05 log units. Additionally, Lepore et al. [44] adopt a very strict criterion of stable responding (i.e., 0.01 log units for three consecutive days), which indicates that the observed effect of 9 -THC in their study could reflect normal baseline variation over days. In most of the studies utilizing the ICSS procedure the criterion of stable responding is defined within 0.1 log units over three consecutive days. At least some of this apparent "discrepancy" can be also explained by the method Lepore et al. [44] used to analyze their data. For example, depending on the criterion used to obtain the critical measurement of threshold in the ICSS paradigm their results appear different. Thus, in Sprague-Dawley rats, 9 -THC exhibits reward facilitating effects only with the 0 criterion, and not the M 50 criterion. It is worth noting that Vlachou et al. [47] analyzed their data with a criterion that resembles the M 50 criterion. In this way, their data are in agreement with the data of Lepore et al. in the Sprague-Dawley strain of rats [44] .
A number of studies have examined the effects of various synthetic cannabinoid agonists and antagonists on brain stimulation reward. Arnold and colleagues [52] have reported that the CB 1 receptor agonist CP55,940 did not affect the reinforcing properties of medial forebrain bundle (MFB) self-stimulation. Similarly, in a series of studies from our laboratory we have shown that the CB 1 receptor agonists WIN55,212-2, CP55,940, HU-210 and AMG-3 either do not affect or increase intracranial self-stimulation threshold, depending on the dose used [53] [54] [55] . In an analogous manner, we have recently shown that the indirect cannabinoid agonists PMSF, AM-404, OMDM-2 and URB-597 either do not affect or increase intracranial self-stimulation threshold, depending on the dose used [56] . Low doses of the CB 1 receptor antagonists SR141716A and AM-251 do not appear to affect brain reward threshold [53, 55, 56] . On the other hand, it has been shown that high and likely non-selective doses of the CB 1 receptor antagonist SR141716A increase brain stimulation reward threshold [52, 57] . However, in such high doses it is possible that SR141716A could act as a partial or inverse agonist at cannabinoid receptors, as it has been observed in other studies [58] [59] [60] . This could be a plausible explanation for its anhedonic effects observed with high doses on brain stimulation reward. Interestingly, clinical studies indicate that SR141716A (rimonabant) may induce anhedonic states and depressed mood [61] .
In summary, the majority of the studies using the ICSS paradigm failed to show any reward facilitating effects for 9 -THC or other cannabinoids, or on the contrary, they present data for anhedonic actions of these compounds, at least in the high dose range. In the studies by Gardner's group the reward facilitating effect of 9 -THC in the ICSS paradigm was only found in rats of the Lewis strain. Although one can speculate that the reinforcing effect of cannabinoids may only be obtained in certain strains of rat, suggesting an important genetic component in this action, other studies have shown that 9 -THC produces aversion in the conditioned place preference paradigm [62] in the same strain of rats, as discussed below.
CANNABINOID SELF-ADMINISTRATION
Human subjects and laboratory animals will selfadminister addictive drugs by a variety of routes, including oral, intragastric, intraperitoneal, and intracranial routes. Intravenous drug self-administration has been one of the most direct approaches to study the rewarding properties of abused drugs in experimental animals, whether rodents or primates. In this behavioral paradigm, animals are given the opportunity to self-administer intravenously a drug by making an operant response, such as pressing a lever in an operant chamber or inserting their nose into a hole [63] [64] [65] [66] . In other words, the model studies directly drug-taking behavior in sub-human subjects. Reinforcing effects of a drug assessed by intravenous self-administration procedures in experimental animals are considered one of the most reliable predictors of abuse potential in human subjects.
Generally, most drugs abused by humans, including psychostimulants, opiates, ethanol, and nicotine, support reliable and persistent self-administration behavior in drug naïve experimental animals [67] [68] [69] . However, for many years, it has been rather difficult to show self-administration of cannabis or 9 -THC in rodents or primates [70] [71] [72] [73] [74] [75] [76] . Interestingly, different research groups have varied the parameters of self-administration procedure in order to demonstrate reliable and persistent self-administration of 9 -THC or other synthetic cannabinoids in experimental animals ( Table 2) .
The first successful self-administration of cannabis is reported by Deneau and Kaymakcalan [77] and Kaymakcalan [78] , who demonstrated acquisition of 9 -THC selfadministration behavior in two monkeys out of six studied, but only after withdrawal from forced automatic i.v. injections of 9 -THC, when signs of physical dependence on 9 -THC occurred. Furthermore, one monkey exhibited 9 -THC self-administration behavior following cocaine selfadministration. Naïve monkeys did not self-administer 9 -THC. Other studies also have shown self-administration of 9 -THC in experimental animals pretreated with phencyclidine [79] or cocaine [80] . Furthermore, in the study by Pickens et al. [79] rates of responding were relatively low and there was no clear evidence that responding for 9 -THC could persist above vehicle control levels over repeated daily sessions. After all, as it has been shown, previous drug exposure can be an important factor in modulating acquisition and maintenance of self-administration of various abused drugs in experimental animals [67, 81] . In other words, the functional state as well as the motivational state in naïve animals compared with animals that self-administer other drugs could be different, and therefore their corresponding response could also vary accordingly. Interestingly, other studies have failed to show robust 9 -THC selfadministration, even in animals pre-exposed to other drugs of abuse, such as cocaine, phenobarbital, phencyclidine, ethanol or amphetamine [72, 75] .
In another frequently used procedure to study the selfadministration of cannabinoids food deprivation was used to initiate and subsequently maintain drug self-administration. However, this manipulation may also alter the motivational state of the animal, which per se is an inherent limitation. Indeed, as it has been repeatedly shown food restriction can facilitate the initiation of drug self-administration [82] [83] [84] [85] [86] .
Earlier studies by Takahashi and Singer [87, 88] reported 9 -THC self-administration above placebo levels in dietrestricted rats maintained at 80% of normal body weight, under conditions where a food pellet was automatically delivered every minute. Interestingly, self-administration immediately decreased to placebo levels when food restriction was discontinued. In a later study by Fattore et al. [89] , rats under food restriction could self-administer intravenously several doses of the CB 1 receptor agonist WIN55,212-2. This effect was blocked by the CB 1 receptor antagonist SR141716A, indicating that the self-administration of WIN55,212-2 was mediated by activation of the CB 1 receptors. The same group replicated this finding in more recent studies using the same experimental design [90, 91] . However, the food restriction protocol used by the authors may have changed the motivational state of the animals, leading to self-administration. Very recently, Lecca et al. [92] reported self-administration of WIN55,212-2 in rats following a different experimental protocol from that of Fattore et al. In their study, rats were not food-restricted, but they were maintained on a daily ration of 20 g of food, made available at the end of each self-administration session. Unequivocally this is another experimental manipulation that may skew the obtained results. In another study by Martellotta et al. [93] , WIN55,212-2 was intravenously self-administered in mice in a dose-dependent manner. This effect was also blocked by pre-treatment with the CB 1 receptor antagonist SR141716A, indicating the direct involvement of the CB 1 receptors. Ledent et al. [94] used the same procedure as Martellota et al. [93] to study the reinforcing effects of WIN55,212-2 in CB 1 knockout mice. As expected, the genetically modified mice did not self-administer WIN55,212-2. One more study has shown that drug naïve mice self-administer the synthetic CB 1 receptor agonist WIN55,212-2 and the 9 -THC derivative HU-210 [95] . However, it should be emphasized that these studies have an important inherent limitation: they employed 1-day experimental tests. Thus, it is difficult to correlate these data with drug addiction which is a chronic state. Furthermore, since the animals were severely restrained, the reported self-administration could not be directed by the positive reinforcing effects of the drug, but rather by analgesic or anxiolytic effects resulting in a reduction of pain or stress produced by the restrain. However, in a later study Justinova and colleagues [96] showed for the first time that low doses of 9 -THC can initiate and sustain high rates of intravenous self-administration in drug-naïve squirrel monkeys. In their study they used 3 drug naïve squirrel monkeys, low doses of 9 -THC (1-8 μg/kg/injection) that according to the authors were several times lower than doses generally used in previous attempts to demonstrate 9 -THC selfadministration in monkeys and comparable to those delivered by an average marijuana cigarette. Furthermore, 9 -THC was dissolved in a Tween-80 vehicle resulting in a clear solution that was rapidly delivered (0.2 ml injection delivered in 200 ms) in drug-naïve animals. The selfadministration behavior was rapidly extinguished either by substituting vehicle injections for 9 -THC injections or by administering the CB 1 receptor antagonist SR141716A before the session, demonstrating that this effect was mediated by direct stimulation of the CB 1 receptors. Interestingly, the same group has recently shown that squirrel monkeys selfadminister the endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide [97] . The authors report rates of responding comparable with those maintained under the same conditions by cocaine or 9 -THC. However, we should mention that in their latter study 4 out of 6 squirrel monkeys had a history of 9 -THC or methohexital selfadministration [97] .
A few studies have examined the possibility that 9 -THC or other cannabinoid analogs are intracranially selfadministered by experimental animals. Braida et al. reported for the first time that the synthetic CB 1 receptor agonist Increase, Decrease in Self-Administration (SA).
CP55,940 is self-administered intracerebrally by rats in a free-choice procedure [98] . This effect was antagonized by the CB 1 receptor antagonist SR141716A, indicating that it was specifically mediated by the CB 1 receptors. However, one limitation of this study is that the animals were waterdeprived and water was concurrently delivered with each infusion. This may have altered the motivational state of the animals, provoking the self-administration response. It should be emphasized that CP55,940 was not self-administered by rhesus monkeys in the study by Mansbach et al. [75] . In a follow-up study, Braida and colleagues reported intracerebroventricular self-administration of 9 -THC in the rat, although under water deprivation conditions, as in their previous study [99] . Recently, Zangen et al. [100] identified two possible brain sites for the rewarding effects of the reported intracerebral self-administration of 9 -THC: the posterior ventral tegmental area and the shell of the nucleus accumbens. In their study, animals self-administered 9 -THC directly into the posterior ventral tegmental area and the shell of the nucleus accumbens, but not in the core of the nucleus accumbens or the anterior ventral tegmental area or the region dorsal to this.
To conclude, most attempts to obtain a robust self-administration of 9 -THC or other synthetic cannabinoids, under normal experimental conditions (i.e., drug naïve animals, not restrained and without previous drug exposure or food deprivation), have been negative. Only a limited number of studies report a robust procedure for cannabinoid self-administration either in a limited number of squirrel monkeys or intracerebrally in rodents. This illustrates the differential status of cannabinoids as atypical drugs of abuse.
CANNABINOIDS EFFECTS ON CONDITIONED PLACE PREFERENCE/AVERSION
The conditioned place preference (CPP) procedure provides an animal model of the subjective, motivational effects of drugs as well as non-drug stimuli [101] [102] [103] [104] . A drug is injected and the animal is placed in a test chamber with distinctive environmental cues (e.g., tactile, visual, and/or olfactory). This procedure is repeated for several days. During these conditioning trials the animal learns an association between the subjective state produced by the drug (e.g., a heightened feeling of euphoria comparable to pleasure in humans) and the environmental cues present during the drug state. When the subject is tested in an apparatus that contains the drug-related environmental cues in one compartment and neutral cues in another, it voluntarily spends more time in the compartment associated with the drug-related cues. In other words, in the CPP procedure neutral environmental cues acquire incentive salience which is closely related to the subjective state produced by the drug. Although the CPP paradigm does not directly measure drug reinforcement, it can be used to infer the motivational values of addictive drugs. Indeed, the concordance with intracranial selfstimulation and self-administration studies is fairly good [102, 104, 105] . Thus, CPP produced by a drug indicates that it exhibits rewarding properties and that it might therefore have abuse potential in humans [105] . A similar place conditioning procedure can also be used to study the aversive properties of a drug or a non-drug stimulus. In this case, the animal will avoid staying in a compartment previously associated with a drug producing aversive or dysphoric effects.
While most drugs abused by humans are able to increase the time spent in the drug-associated compartment, producing a clear place preference, the corresponding data on cannabinoids are not very consistent. Indeed, 9 -THC and other synthetic cannabinoid agonists can induce both appetitive and aversive effects in the CPP paradigm under various experimental conditions (Table 3) . Notably, in most of the studies reporting place preference of cannabinoids these effects are usually dependent upon the particular dose used and the preference is connected to a single dose. However, this is not the case with typical drugs of abuse, in which place preference can be obtained over a range of doses [101] [102] [103] [104] . Furthermore, the timing between injections has been suggested as another important factor determining whether cannabinoids produce preference or aversion [106] , since pharmacokinetic factors (i.e. factors related to bioavailability of the drug formulation used, lipophilicity, distribution and storage in fat tissue, metabolism and elimination rate) seem to be responsible in part for the subjective effects of cannabinoids.
A number of studies in rodents failed to show that 9 -THC produces conditioned place preference, or revealed clear aversive phenomena [62, [107] [108] [109] [110] [111] [112] [113] . In an attempt to show CPP on 9 -THC or other cannabinoids many groups manipulated the experimental conditions, and more specifically the timing of injections as well as the range of the doses used.
The first report in which 9 -THC produced conditioned place preference was published in 1995 by Lepore et al. [106] . In their study, 2-4 mg/kg 9 -THC produced conditioned place preference in Long Evans rats when the CPP pairing interval was 24 h; using the same experimental design, 1 mg/kg of 9 -THC did not produce any preference. However, in the same study, when the schedule of daily injections was changed, allowing a longer wash-out interval between injections (48 h), 9 -THC produced a clear place aversion in the dose of 2-4 mg/kg, but place preference in the dose of 1 mg/kg. The authors attributed these differential responses to the different methodological conditions followed, such as the duration and the number of sessions. In this regard, increasing the time interval between 9 -THC injections might have changed the effects of 9 -THC due to a post-drug dysphoric rebound effect. In other words, at the shorter pairing interval the post-9 -THC rebound dysphoria might have attenuated 9 -THC's rewarding effect, while at the longer pairing interval, where the post-9 -THC rebound effect subsided, the effects of all doses were accentuated, allowing the 1 mg/kg to be rewarding and the highest doses to be aversive. In any case, these unusual results emphasize for one more time that 9 -THC is an atypical, if not an anomalous, drug of abuse.
Similarly, in a study by Braida et al. [99] 9 -THC produced conditioned place preference in Wistar rats in a dose range between 0.075 and 0.75 mg/kg. In the same study, higher doses of 9 -THC (6 mg/kg) produced clear aversive effects. The authors suggested that the low doses of 9 -THC used in their experiment could have minimized any dysphoric effects of the drug that might lead to aversion. More recently, Le Foll et al. [114] reported that a low 0.1 mg/kg dose of 9 -THC produced conditioned place preference. Doses lower (i.e., 0.01 mg/kg) or higher (i.e., 1 mg/kg) than this did not produce any preference.
Valjent and Maldonado in their study [115] bypassed the dysphoric/aversive effects of 9 -THC that has been reported in naïve animals by giving the animals a priming injection 24h before the first conditioning session. In this way, 9 -THC induced clear CPP in mice. However, a more recent study by Vlachou et al. [47] , in which the authors used the same experimental manipulation, no conditioned place preference was observed with the 1 mg dose of 9 -THC. This inconsistency in results could be attributable to the different strain of animals used, the number of pairings or the periods of conditioning and administration of the drugs. Maldonado's group replicated their findings in a more recent study [116] . However, it is worth noting that in the latter study 5 mg/kg 9 -THC produced conditioned place aversion.
Conflicting results have also been reported in the literature for synthetic direct and indirect cannabinoid agonists.
McGregor et al. [117] reported aversive effects of the synthetic CB 1 receptor agonist CP55,940 in the CPP paradigm both in a very low dose of 10 μg/kg as well as in a higher dose of 100 μg/kg. In the same study, only the dose of 100 μg/kg was aversive in the conditioned taste aversion paradigm. It is worth noting that in the ICSS paradigm, Vlachou et al. [55] observed a clear anhedonic effect for the CP55,940 compound when administered in the dose of 100 9 -THC and its analog HU-210 produced conditioned place aversion in the rat, although cocaine and the CB 1 receptor antagonist SR141716A produced a clear preference. The fact that SR141716A produced place preference opens the possibility that an endogenous cannabinoid tone might be present in the brain, as a physiological system to suppress reward or induce aversion [107] . However, in other studies SR141716A failed to produce either place conditioning or place aversion [118, 119] . To the contrary with the studies cited above, Braida et al. [119] reported that CP55,940 elicits a conditioned place preference only in the dose of 20 μg/kg. The authors used a broader time interval between the cannabinoid injections, compared with the study by McGregor et al. [117] , in which a place aversion was shown using a narrow time interval. These findings corroborate those observed in the Lepore et al. study [106] with 9 -THC. Thus, these authors suggested that in the study by McGregor et al. [117] the narrow interval between the cannabinoid injections might lead to a rebound anhedonic or dysphoric state masking the appetitive effects of the drug. The conditioned place preference induced by CP55,940 was fully antagonized by pretreatment with the CB 1 receptor antagonist SR141716A. Recently, Castané et al. [120] also reported that WIN55,212-2 produced conditioned place preference in mice preexposed to a priming injection of the drug.
A limited number of studies have examined the effects of endogenous cannabinoids or compounds increasing their levels in the brain. Mallet and Beninger [110] were the first to report that the administration of the endogenous cannabinoid anandamide did not produce any significant effects in place conditioning, although using the same experimental protocol 9 -THC produced conditioned place aversion. Gobbi et al. [121] in a study investigating the antidepressant properties of URB-597, a compound that blocks anandamide hydrolysis, did not find any rewarding effects in the CPP paradigm. Interestingly, in a later study examining various properties of the anandamide transport inhibitor AM-404, Bortolato et al. [122] showed that AM-404 produced conditioned place preference only in rats housed under enriched conditions, but not in rats kept in standard cages.
In conclusion, while almost all drugs abused by humans are able to produce a clear and reliable place preference (i.e., increase the time spent in the drug paired compartment) over a limited range of doses, results with 9 -THC and other cannabinoids have not always been consistent. The studies reporting a conditioned place preference associated with administration of a cannabinoid have used particular experimental methodology, and the preference often occurs at only a single dose.
CANNABINOID DISCRIMINATION
The pharmacological effects of a drug can include distinct interoceptive cueing effects. These cueing effects can play an important role in the addiction process, such as prompting additional drug-seeking behavior. The standard preclinical rodent model for studying the cueing (discriminative stimulus) effects of a drug is referred to as drug discrimination [123, 124] . In this procedure, animals faced with two possible responses one of which is reinforced (usually with food, under some schedule) while the other is not reinforced. The animals are trained to detect whether they received an active drug or vehicle (no drug) injection, in order to determine through the specific drug effects which response is the correct. Rats (like humans) can readily learn to discriminate between a drug versus a non-drug state pressing the reinforcement-associated lever. The discrimination between drug and non-drug conditions is based upon the presence or absence of subjective and central effects. Although the drug discrimination procedure does not measure directly the reinforcing/rewarding effects of drugs, it can be used to infer if an experimental drug may have abuse potential in humans [125, 126] .
A significant number of drug discrimination studies have shown that cannabinoids produce subjective effects in experimental animals [60, [127] [128] [129] [130] [131] [132] [133] [134] (Table 4) . In particular, cannabinoids show a pharmacological specificity in this behavioral paradigm. In animals trained to discriminate injections of 9 -THC from injections of saline, only drugs that activate CB 1 receptors generalize to the 9 -THC training stimulus [60, [128] [129] [130] [131] [132] [133] 135] . Furthermore, synthetic CB 1 receptor agonists generalize to the 9 -THC training stimulus with a potency that corresponds with their in vitro affinity for the CB 1 receptors [127, 130, 134] . Likewise, CB 1 receptors seem to be selectively involved in these actions, since they can be blocked by SR141716A administration [60, 129, [133] [134] [135] [136] [137] [138] [139] . Moreover, it seems very likely that the cannabinoid cue effect is centrally mediated through the CB 1 receptor subtype, since Pério et al. [139] have shown that the CB 1 receptor antagonist SR140098, which does not cross the blood brain barrier, could not antagonize the discriminative stimulus properties of cannabinoids, and Kallman et al. [140] have shown that intracerebral administration of 9 -THC induced drug appropriate responding in rats trained to discriminate it from vehicle after systemic injections.
In general, experimental animals trained to discriminate a CB 1 receptor agonist from saline showed complete generalization only if they were tested with other CB 1 receptor agonists and not compounds from other pharmacological classes, such as opioids, barbiturates, psychostimulants, hallucinogens, anticonvulsants, neuroleptics and antidepressants [127] [128] [129] [141] [142] [143] . Only a partial overlap in the discriminative stimulus properties between 9 -THC and diazepam, phencyclidine or 3,4-methylenedioxymethamphetamine has been reported [128, 141, 144, 145] . However, in a more recent study the substitutions of both pentobarbital and diazepam for 9 -THC were found to be considerably less pronounced than those reported previously [128, 144] .
Recently, Solinas et al. [146] demonstrated that the discriminative stimulus effects of 9 -THC are potentiated by opioid agonists (morphine) and decreased by opioid antagonists (naloxone). In a follow-up study, Solinas and Goldberg [147] confirmed and extended those findings with heroin and also found that mu but not delta or kappa opioid receptors are involved in the discriminative effects of 9 -THC. Nicotine also potentiated the discriminative effects of low doses of 9 -THC, although it did not produce 9 -THC-like effects [148] .
Furthermore, it has been difficult to reveal a crossdiscrimination between CB 1 receptor agonists and the endocannabinoid anandamide [136, [149] [150] [151] . Only a very high dose of anandamide (45 mg/kg) was able to produce a crossdiscrimination with 9 -THC (3 mg/kg) [151] . However, it must be emphasized that such a high dose of anandamide induced non-specific effects in this behavioral model, such as a decrease in food-maintained responding [151, 152] . This could be explained by the fact that anandamide has a very rapid reuptake and metabolism by the fatty acid amide hydrolase (FAAH). Indeed, the metabolically more stable analogs of anandamide, 2-methyl-arachidonyl-2-fluoroethylamide, R-methanandamide and O-1812, can produce a complete generalization to 9 -THC [136, 137, 142, 149, 150, 153, 154] , although the dose of 9 -THC seems to be an important determinant for the degree of this generalization. However, anandamide has been shown to produce a crossdiscrimination with methanandamide [136] . The discrepancy between the ability of anandamide to produce a crossdiscrimination between methanandamide and not 9 -THC might be related to the different affinity of 9 -THC and methanandamide for cannabinoid receptors, or the possibility that anandamide and methanandamide, but not 9 -THC, interact with a different cannabinoid receptor than the CB 1 .
Recently it has been shown, however, that the crossdiscrimination between methanandamide and 9 -THC is mediated through the CB 1 receptor [137] . Very recently, Solinas et al. [155] showed that methanandamide when injected i.v., produced clear dose-related 9 -THC-like discriminative effects, but anandamide produced 9 -THC-like discriminative effects only at a high dose that almost eliminated lever-press responding. The FAAH inhibitor URB-597 produced no 9 -THC-like discriminative effects alone but dramatically potentiated discriminative effects of anandamide. The 9 -THC-like discriminative stimulus effects of anandamide after URB-597 and methanandamide were blocked by the CB 1 receptor antagonist SR141716A. However, surprisingly in the same study, the anandamide transport inhibitors AM-404 and UCM-707 did not potentiate 9 -THC-like discriminative effects of anandamide. Hence, anandamide substitution for other cannabinoids is, at best, unreliable. This may be due to the fact that anandamide, unlike direct cannabinoid receptor agonists, acts as an endovanilloid and affects also vanilloid receptors.
In summary, drug discrimination with cannabinoids is pharmacologically selective, since 9 -THC fully substituted for other synthetic cannabinoids with affinity for the CB 1 receptor. In contrast, compounds with anandamide-like structure exhibit differences from classical cannabinoids, since in a number of studies they failed to substitute for 9 -THC or other CB 1 receptor agonists. Since 9 -THC-like discriminative stimulus effects can predict cannabis-like intoxication in humans, anandamide-like compounds and drugs that directly affect the endocannabinoid levels may prove promising therapeutics in the future, with less unwanted side effects and minimal abuse potential.
BEHAVIORAL SENSITIZATION TO CANNABI-NOIDS
Behavioral sensitization is a progressive and enduring enhancement in a behavioral response (usually motor behavior) to the administration of constant or incrementally enhanced doses of a drug. Sensitization processes are subject to complex neurobiological alterations that persist for a long time and are thought to play an important role in the development and maintenance of drug addiction by a process in which a simple liking of the drug becomes sensitized up to the point where loss of control and drug craving is manifested [156] . Basically, drugs that humans abuse also produce behavioral sensitization [157] . Accordingly, if a drug produces behavioral sensitization upon repeated administration it might have abuse potential in humans. Whether cannabinoids, and in particular 9 -THC, produce similar effects in this model is somewhat controversial, with mixed evidence in the literature ( Table 5) .
A pattern of behavioral sensitization after repeated administration of 9 -THC has been reported in the literature in the rat [158] [159] [160] . However, the behavioral sensitization observed in those studies were mainly characterized by oral stereotyped items and were less intense and shorter than that induced by typical drugs of abuse, such as morphine [161] . Furthermore the experimental protocol used comprised of escalating dose regimen and not a constant dose, as it has usually been investigated with typical drugs of abuse [162] [163] [164] . Recently, Varvel et al. [165] did not observe behavioral sensitization in mice after repeated exposure to 9 - THC, although with the same experimental procedure they observed a clear behavioral sensitization to methamphetamine. Similarly, in a recent study by Kolb et al. [166] , rats showed no evidence of sensitized locomotor activity after repeated treatment either with a constant dose or escalating doses of 9 -THC. A failure for 9 -THC to induce behavioral sensitization has also been observed in a study by Wu and French [167] . Interestingly, in this study, 9 -THC acutely produced hypoactivity, which was diminished with repeated exposure to the drug, indicating the development of tolerance to this effect. To our knowledge, in the relevant literature behavioral sensitization following repeated exposure to synthetic cannabinoid agonists or endocannabinoid modulators has not so far been reported.
In summary, cannabinoids do not share with other drugs of abuse the potential to produce clear and robust behavioral sensitization. The fact that the relevant neuronal circuits which are responsible for the phenomenon of sensitization observed with typical drugs of abuse, failed to become sensitized after repeated exposure to cannabinoids, may explain why marijuana abuse in the human population usually is not accompanied by obsessive-compulsive drug-seeking behavior.
CANNABINOID TOLERANCE
Tolerance can be defined operationally as a right-or downward shift in a dose-effect function, so that higher doses of the drug are required to produce the same effect. Unequivocally this process represents an adaptation to a specific drug effect. Many aspects of tolerance have been hypothesized to play important modulatory roles in the development of physical dependence. However, regular drug exposure might well lead to tolerance regardless of weather physical dependence occurs. Interestingly, under specific circumstances it has been shown that tolerance and physical dependence can be dissociated and that they can have distinct molecular mechanisms (e.g., [168] ).
Acute or subchronic administration of 9 -THC or other cannabinoid agonists in laboratory animals produces multiple neurobiological effects including sedation, catalepsy, motor inhibition, suppression of operant behavior, ataxia, incoordination, analgesia, anticonvulsing activity, memory impairment, antiemetic effect, hypothermia and increased appetite [169] . Cannabinoids also produce a variety of peripheral effects, such as hypotension, reduction of intraocular pressure, immunosuppression, intestinal hypomotility, and changes in adrenal function [170] . Although there is little evidence for the development of sensitization in the cannabinoid system (see previous section), there is ample evidence indicating that in most of the central and peripheral effects of cannabinoids tolerance develops when the administration prolongs for several days in laboratory animals [171, 172] (Table 6a) .
Tolerance has been reported in various species [173] , but the degree and the time-course are dependent on the species used, the agonist's efficacy, the dose, the duration of the treatment, and the experimental procedures used to determine tolerance, as well as the system in which it is assessed [171] . The development of cannabinoid tolerance is remarkably rapid and culminates soon after the start of the chronic treatment [174] [175] [176] [177] . However, although tolerance for certain pharmacological effects of cannabinoids, such as analgesia, motor inhibition, hypothermia, discriminative stimulus effects develops typically within the range of 3-7 days [131, 175, [178] [179] [180] [181] , other effects, such as the appetite stimulant, the antiemetic, the antihyperalgesic, memory impairment and neuroendocrine effects either do not develop tolerance or they require weeks for such a development or larger doses of the compounds [182] [183] [184] [185] [186] [187] [188] .
Similarly, tolerance to anandamide-induced suppression of spontaneous activity, antinociception, catalepsy, hypothermia, and the twitch response in mouse vas deferens has also been reported [180, [189] [190] [191] [192] [193] [194] , although the magnitude of tolerance tended to be lower than that for 9 -tetrahydrocannabinol [193, 194] .
The development of cannabinoid tolerance is mostly pharmacodynamic in nature (down-regulation/desensitization of cannabinoid receptors), and the contribution of pharmacokinetic properties of cannabinoids (changes in drug absorption, distribution, biotransformation, and excretion), if any, seems minor [195] [196] [197] [198] . In fact, a significant reduction in the total number of CB 1 receptors, which are predominant in the central nervous system, along with an attenuation of G-protein activation has been repeatedly shown after chronic administration for most cannabinoids [199] . These adaptive responses occur in all brain regions that express cannabinoid receptors, but there is a regional variability both in the rate and the magnitude of this response [171, 199] . Nevertheless, there have also been reports of increased receptor binding [200] or no change in receptor binding in whole brain [201] during the development of tolerance. Furthermore, chronic exposure to 9 -THC has also been shown to produce regiondependent alterations in brain endocannabinoid levels in the rat. Specifically, anandamide concentrations were increased in the limbic forebrain and decreased in striatum, midbrain and diencephalon in 9 -THC tolerant rats, whereas 2-arachidonoylglycerol concentrations increased in the cerebellum, brainstem and hippocampus, and decreased in the striatum [202, 203] . Tolerance at least to some of the pharmacological effects of cannabinoids dissipated from 7 to 11 days after the end of the chronic cannabinoid exposure [175] . This effect fits very well with the reported reversal of the adaptive changes in the CB 1 receptors even after long-term treatment with 9 -THC [204] . Interestingly, the CB 1 receptor antagonist SR141716A did not always block the development of tolerance to central behavioral actions of cannabinoids, such as motor incoordination [176] . This finding is very unusual, and may be related to the long duration of 9 -THC action.
As might be expected, cross-tolerance has been reported between different exogenous CB 1 receptor agonists [178, 180] (Table 6b) . However, controversial results have been reported on the possible cross-tolerance between anandamide or its metabolically stable analogs and 9 -THC. Fride [191] demonstrated cross-tolerance to the antinociceptive, hypolocomotor, cataleptic and hypothermic effect between 9 -THC and anandamide in female mice, but not to the decreased defecation. On the contrary, Pertwee et al. [180] did not report cross-tolerance between 9 -THC and anandamide to their hypothermic effect. Similarly, Welch [193] did not show cross-tolerance between 9 -THC and anandamide to the antinociceptive effect in the rat. Recently, Wiley et al. [181] in a very elegant study examined the possible crosstolerance between 9 -THC and anandamide-like compounds (anandamide, 2-methylanandamide, and O-1812) in tests sensitive to cannabinoid action, including spontaneous activity, tail flick, rectal temperature, and a ring immobility test of catalepsy. According to their report the degree of crosstolerance between 9 -THC and anandamide-like cannabinoids depended upon the specific drug and the measure. Whereas repeated dosing with 9 -THC induced tolerance to all effects, cross-tolerance with anandamide analogs was observed for antinociception (all three compounds), suppression of spontaneous activity (2-methylanandamide and O-1812), catalepsy (O-1812), but not for hypothermia. These seemingly contradictory results open the possibility that a different population of receptors might be involved in producing these effects. Indeed, the different pharmacological actions between cannabinoid receptor agonists and anandamide may be due to the fact that anandamide also acts as an endovanilloid and affects vanilloid receptors. After all, these results suggest that anandamide interaction with brain cannabinoid CB 1 receptors may differ from that of 9 -THC or that multiple brain cannabinoid receptors may exist, as already has been suggested by many studies.
Interestingly, rating of "high" in human marijuana users has been reported to remain stable in magnitude over time, despite repeated marijuana administration. Still, people who use high doses of cannabis over a long period may not perceive a strong high anymore [205] [206] [207] [208] . Thus, the issue of tolerance development of the subjective/pleasurable effects of marijuana remains open, and implies that not all effects of cannabinoids develop tolerance. Accordingly, Whitlow et al. [209] have shown that although following chronic 9 -THC exposure in rats the magnitude of acute cerebral metabolic alterations diminished throughout most brain regions after the first 7 days of exposure, in a subset of structures localized within the mesocorticolimbic system, which is involved in motivated behaviors and drug addiction, remain functionally active even after 21 days of treatment. To the same direction, rats chronically treated with 9 -THC developed tolerance to 9 -THC-induced increases in firing rate of dopamine neurons in substantia nigra neurons, but not in the ventral tegmental area neurons, which continue to show increases in their firing rate [167] . Thus, the failure of ventral tegmental area dopamine neurons to undergo tolerance after long-term 9 -THC may be related to the reported observations that subjective/pleasurable effects of marijuana in humans also do not undergo pronounced tolerance after chronic administration of the drug [208, 210] . After all, this is a substantial difference between 9 -THC and typical drugs of abuse.
An interesting point to mention relates the behavioraltherapeutic effects of cannabinoids with the dose range and the development of tolerance. Therapeutic effects of cannabinoids appear to occur at low to moderate doses. [182, 183, 185] , whereas the classic cannabinoid behavioral syndrome (suppression of spontaneous activity, antinociception, hypothermia, and catalepsy) appears only in relative high doses [211] . In addition, tolerance appears to develop very rapidly to the cannabinoid behavioral syndrome [178, 183] , but not to the potential therapeutic effects of cannabinoids [182, 183] . This is a good indication that the tolerability window of cannabinoid will not change upon repeated administration of the drug. After all, the advantage of a lowdose administration is twofold: first, it could delay the acquisition of tolerance or desensitization; and second, could minimize other unwanted side-effects that might be produced.
Although we can conclude that chronic exposure to cannabinoids provokes adaptive changes in the endocannabinoid system accompanied by CB 1 receptors down-regulation and attenuation of G-protein activation, little is known about their functional consequences when cannabinoid administration is abruptly terminated after a prolonged exposure. This is related with the questionable issue whether the tolerance observed after chronic cannabinoid administration signifies physical dependence. Indeed this happens with other drugs of greater recognized addictive potential that also produce clear withdrawal reactions upon cessation. We will approach this issue in the next section.
CANNABINOID PHYSICAL DEPENDENCE/WITH-DRAWAL
Although the process of physical dependence and withdrawal is not directly related to the reinforcing/rewarding effects of drugs, it is closely related to drug addiction. Almost certainly, the process of physical dependence and the manifestation of withdrawal contribute to the development [181] and maintenance of drug addiction through negative reinforcement processes [212] [213] [214] . On the other hand, the development of physical dependence and the manifestation of withdrawal symptoms limit the use of many drugs in the clinic.
Two procedures are commonly used to investigate the development of physical dependence and the occurrence of withdrawal syndrome in laboratory animals. The first is the abstinence withdrawal procedure, in which following repeated administration of a drug, it is abruptly discontinued and the physical signs that emerge are evaluated (spontaneous withdrawal). In the second procedure, the precipitated withdrawal, an appropriate receptor antagonist is administered to animals that have been made dependent upon a drug (the agonist). The rationale of this model is that the antagonist displaces the agonist from the appropriate receptor, eliciting molecular changes and withdrawal signs that can easily be evaluated.
In addition to the somatic aspects of drug withdrawal, another relevant symptom, which is closely related to the brain reward circuit, is anhedonia. Anhedonia is a core symptom in both depression and drug withdrawal and can be investigated using the ICSS paradigm, as elegantly has been shown by Markou and colleagues [215] [216] [217] . In this case, ICSS thresholds are used operationally as a measure of the animals' "hedonic-anhedonic" state. ICSS thresholds are found to be elevated under withdrawal conditions from many drugs of abuse, including psychostimulants, opiates, alcohol, nicotine, and phencyclidine. This reflects an "anhedonic" state for the animal exhibiting drug withdrawal.
Although experimental animals treated chronically with typical drugs of abuse exhibit withdrawal reactions either following drug cessation or upon the administration of the appropriate receptor antagonist, data on cannabinoids are largely contentious (Table 7) . Thus, there is no general agreement whether cannabinoid tolerance can produce physical dependence, as has been demonstrated with typical drugs of abuse. First of all, several studies failed to report spontaneous withdrawal symptoms following chronic 9 -THC administration in experimental animals [72, 73, 177, [218] [219] [220] [221] [222] . It has been proposed that the main reason for this is the particular pharmacokinetic properties of 9 -THC [171] [172] [173] 223] . Indeed, its high lipophilicity, the long duration and the slow metabolic clearance may prevent the development of a pronounced withdrawal syndrome, when the drug is abruptly discontinued. This may also explain the general contention that cannabis withdrawal syndrome is seldom in recreational cannabis users, or when appeared it is mild and clinically insignificant (DSM-IV, [224] ). Indeed, most scientists agree that a reliable cannabis withdrawal syndrome may emerge only following discontinuation of heavy use of cannabis preparations [2, 225] . To our knowledge, the only study in rats reporting a spontaneous withdrawal reaction after chronic 9 -THC treatment has been published by Kaymakcalan et al. [226] . However, in this study, the authors treated the rats for 5 weeks with extremely high doses that the last two weeks reached 40mg/kg twice daily. In spite of the failure to observe clear spontaneous withdrawal reactions following 9 -THC cessation, Beardsley et al. [227] reported a suppression of operant behavior for food reinforcement in monkeys. The authors interpreted this specific condition as a manifestation of spontaneous withdrawal, since it returned to normal after re-administration of the drug. In a latter study, they replicated the same behavioral pattern in rats [228] . Fredericks and Benowitz [229] also reported that following discontinuation of 9 -THC, monkeys showed an increase in gross movement, eye contact, and tooth bearing of greater frequency and/or duration than observed before 9 -THC. The authors suggest that this may represent a cannabis abstinence syndrome. However, these manifestations deviate from the view of the classical withdrawal syndrome observed with typical drugs of abuse.
Only three studies have reported the occurrence of spontaneous cannabinoid withdrawal following chronic treatment with synthetic cannabinoid agonists [230] [231] [232] . However, it should be emphasized that these studies used synthetic agonists of powerful pharmacological potency for the cannabinoid receptors (WIN55,212-2 and CP55,940), compared to 9 -THC, and with a substantial different pharmacokinetic profile. Furthermore, the spontaneous withdrawal observed was not very pronounced, but rather mild and particularly modest compared with other studies in which precipitated withdrawal from cannabinoids was manifested. In a more recent study in rats, Moreno et al. [233] observed, following withdrawal of chronic treatment with the CB 1 receptor agonist HU-210, a decrease in spontaneous motor activity, which was interpreted as an aspect of withdrawal reaction. To the contrary, Oliva et al. [231, 232] reported during spontaneous withdrawal from CP55,940 a marked increase in motor activity and exploratory behavior along with decreases in the number of groomings, rubbings and wet-dog shakes. Abrupt cessation of treatment with CP55,940 does not induce the classic somatic signs of withdrawal observed after cannabinoid antagonist-precipitated withdrawal. This may be related to the different experimental protocol (i.e. spontaneous vs precipitated), the different agonists used or the different timing of the dosing regimen.
In the absence of a clear spontaneous withdrawal from 9 -THC in experimental animals a number of investigators have tried to demonstrate physical dependence and withdrawal signs by challenging chronically treated animals with a CB 1 receptor antagonist, such as SR141716A. In fact, administration of the CB 1 receptor antagonist SR141716A in experimental animals chronically treated with 9 -THC precipitates specific withdrawal reactions. The signs observed are largely somatic (mainly of motor nature), with no relevant vegetative changes. The most characteristic withdrawal signs in rodents are wet-dog shakes, head shakes, facial rubbing, front paw tremor, body tremor, ataxia, eyelid ptosis, piloerection, hypolocomotion, retropulsion, licking, scratching and mastication [94, 109, 116, 203, 218, [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] . Similar precipitated withdrawal reactions have also been observed following chronic treatments with synthetic cannabinoid agonists [245] [246] [247] [248] [249] . These somatic signs, even if they appear very mild, are mediated through the CB 1 receptor, since in CB 1 knockout mice receiving chronic treatment with 9 -THC administration, the CB 1 receptor antagonist SR141716A did not precipitate any signs of abstinence [94] . However, in most of the above mentioned studies the authors used extreme large doses of cannabinoid agonist and/or antagonist. This may have complicated the obtained results. [190] For example, Rodriguez de Fonseca et al. [248] observed even in rats chronically treated with vehicle that SR141716A elicits some withdrawal signs (spontaneous withdrawal). Interestingly, in 9 -THC-dependent dogs, SR141716A precipitated a unique pattern of withdrawal signs that included diarrhea, vomiting, excessive salivation, decreases in social behavior, and increases in restless behavior and trembling [250] .
Only two studies have examined the possibility that endocannabinoids, such as anandamide, might produce physical dependence when administered exogenously; their results move in opposite directions. Aceto et al. [251] in a very elegant study showed that abrupt discontinuation of anandamide infusion in rats did not elicit any withdrawal responses; furthermore, neither SR141716A was able to precipitate withdrawal reactions in those rats. The authors decided to administer the drug through continuous infusion (rats were infused i.p. on a continuous basis with anandamide [25-100 mg/kg/day] for 4 days), in order to address its rapid metabolism. Furthermore, they examined if the putative, metabolically stable anandamide analog 2-Me-F-AN could produce physical dependence (5-20mg infused for 4 days). Even with the use of 2-Me-F-AN they were unable to demonstrate signs of physical dependence. Accordingly, it seems unlikely that the failure of chronic anandamide to produce physical dependence signs is related to its short half-life or metabolism.
On the other hand, rats injected i.p. for two weeks with anadamide (20mg/kg) displayed a withdrawal reaction both upon abrupt cessation and under a challenge with ( SR141716A [190] . The withdrawal signs observed in that study resemble those observed with other cannabinoid agonists and include scratching, licking and biting, eating of feces, ptosis, arched back, wet-dog shakes, head shakes, myoclonic spasms, writhing, forepaw fluttering, teeth chattering and piloerection. The different findings in these two studies are likely due to the different experimental protocol employed (length of drug exposure, timing of injections, dose range of anandamide and SR141716A used, behavioral method to measure withdrawal). To our knowledge, there is no study in the literature examining if drugs that protect endocannabinoids from endogenous inactivation may produce physical dependence upon repeated administration.
Although most drugs of abuse upon withdrawal after chronic treatment exhibit a clear "anhedonic" state as reflected in elevated ICSS thresholds [215] [216] [217] , this has not been investigated properly with cannabinoids. Gardner and Vorel [43] report that "withdrawal from as little as a single 1.0 mg/kg dose of 9 -THC produces significant elevations in electrical brain stimulation thresholds". However, in our opinion it seems rather unusual that a single and relatively low dose of 9 -THC could produce dependence, in order to observe withdrawal anhedonia, as typically more robust regimens of administration are employed for other drugs of abuse to study these neurobiological phenomena. Since Gardner and colleagues in their studies adopt a very strict criterion of stable responding (i.e., 0.01 log units for three consecutive days), it is possible that the observed effect of 9 -THC in their study could reflect normal baseline variation over days.
In summary, there is no conclusive evidence for a robust spontaneous withdrawal in experimental animals treated chronically with 9 -THC. The analogous precipitated withdrawal, or the withdrawal observed after chronic treatment with potent synthetic CB 1 receptor agonists has been shown using very high doses of 9 -THC or the equivalent CB 1 receptor agonists, which exceed the relevant dose range in human cannabis users [252] . Regarding endocannabinoids, the available data are limited and contradictory; this make it difficult to conclude if the endogenous substances have addictive potential, much more since we do not, as yet, know if agents capable to protect endocannabinoids from endogenous inactivation produce any physical dependence and/or withdrawal.
NEUROCHEMICAL EFFECTS OF CANNABINOIDS ON DOPAMINE RELEASE IN THE NUCLEUS AC-CUMBENS IN VIVO
It has been well established that certain typical drugs of abuse, e.g. psychostimulants, opiates, ethanol, and nicotine, increase dopamine release in the nucleus accumbens, a main projection area of the ascending mesotelencephalic dopaminergic system (also referred to as mesolimbocortical dopaminergic projection), in experimental animals in vivo [253] . This effect has been considered as a neurochemical hallmark of the dependence-producing properties and abuse potential of these classes of drugs, given the intricate involvement of the mesolimbocortical dopaminergic projection in processes related to reinforcement of behavior, hedonic homeostasis and incentive salience attribution to intero-and exteroceptive physiological and pharmacological stimuli [254, 255] . Acute administration of addictive drugs typically increases dopamine release in the nucleus accumbens, especially in the shell subdivision, to a greater extent than in other projection areas, e.g., the striatum and the core of the nucleus accumbens [256, 257] . This action is either maintained or even enhanced after repeated administration depending on the conditions and the context of administration [258] [259] [260] . Additional work on the exact site(s), mechanism(s) of drug action and related physiological consequences has revealed important information on where and how addictive drugs act to mediate their stimulatory effects on dopamine and how these neurochemical changes interface with and shape behavioral and physiological responses [261, 262] . Importantly, drug withdrawal elicited either spontaneously or after precipitation with specific receptor antagonists seems to result in a consistent reduction of dopamine release in the nucleus accumbens that has been related to dysphoria and emotional distress often exhibited by dependenceproducing substances in an abstinence state [263] .
The cannabinoid agonist 9 -THC increases dopamine release in the major projection areas of the ascending dopaminergic system of experimental animals in vivo, as assessed by microdialysis (Table 8) , similarly to many, but not all, drugs of abuse. Several methodological parameters, such as the route of administration, the strain of animals used, and the dopaminergic projection area sampled appear to be major determinants of the robustness and reproducibility of this neurochemical effect [90, 223, [264] [265] [266] [267] [268] [269] [270] [271] [272] . Tanda et al. [269] in a critical study showed beyond any doubt that both 9 -THC and WIN55,212-2 administered intravenously increase dopamine release selectively in the shell of the nucleus accumbens, through stimulation of CB1 receptors, and confirmed previous work by Chen et al. [264] that opioid receptor stimulation plays an important role in the observed finding. Interestingly, chronic administration of 9 -THC did not affect basal release of dopamine in the shell of the nucleus accumbens, but challenge with SR141716A in these animals decreased accumbal dopamine release, representing a neurochemical response related to precipitated withdrawal, similarly to other drugs of abuse [273] . In direct relevance to behavioral responses that are indicative of the dependenceproducing properties of psychotropic compounds, it was recently shown that self-administration of WIN55,212-2 is associated with an increase in DA release in the nucleus accumbens [91, 92] . In terms of the effects of endocannabinoids on dopamine release in the brain, Solinas et al. [155, 274] showed that intravenous, but not intraperitoneal, administration of anandamide and its longer-lasting analog, methanandamide, increase dopamine release in the nucleus accumbens in a multiphasic manner with a differential involvement of the CB1 receptors. It is striking, however, that the same authors did not find an effect of the endocannabinoid neurotransmission enhancers URB597 and AM404 administered intraperitonally on accumbal dopamine release, in spite of the fact that these compounds increase endocannabinoid levels in plasma and brain and potentiate anandamide's stimulatory action on dopamine release [155, 274] . Thus, the route of administration of endocannabinoids or their modulators (see also, [275] ) and the mechanism underlying the enhancement of endocannabinoid neurotransmission seems to be of major importance in determining effects on dopamine release in the nucleus accumbens.
Taken together, it is safe to conclude that cannabinoid agonists and endocannabinoid modulators affect dopamine release in the nucleus accumbens in a very "idiosyncratic", i.e. related to this particular class of compounds, manner, in which methodological variables are critical. Clearly, more work is required to fully understand the pharmacokinetic/pharmacodynamic dimensions of the effects of cannabinoids on dopamine release and the relevance of this phenomenon to their behavioral actions. Specifically, full dose-response curves after different routes of administration in the presence or absence of selective antagonists (or genetic invalidation of cannabinoid targets) and in relation to behavioral or physiological responses need to be obtained, and the site(s) and mechanism(s) of action fully disclosed. In addition, the actions of endocannabinoids and endocannabinoid modulators on this neurochemical parameter need to be studied further, as new selective compounds are developed and the dynamics of endocannabinoid neurotransmission elucidated. To the extent that an enhancement of dopamine release in the nucleus accumbens is directly related to the dependence-producing properties of a studied class of compounds, it remains of paramount importance to reveal the details of the interaction of cannabinoids with the dopaminergic system in order to assess their addictive potential.
CONCLUDING REMARKS
Different animal models are now available to examine motivational/reinforcing and dependence-producing properties of cannabinoids. These models are similar to those used for other drugs of abuse. Studies using these behavioral models to date suggest that particular experimental conditions are required to reveal cannabinoid motivational/reinforcing properties and abuse potential in experimental animals. Specifically, the majority of the studies using the ICSS paradigm failed to show any reward facilitating effects for 9 -THC or other cannabinoids, or on the contrary, they present data for anhedonic actions of these compounds, at least in the high dose range. Similarly, most attempts to obtain a robust self-administration of 9 -THC or other synthetic cannabinoids, under typical, drug-free experimental conditions, have been negative and only a limited number of studies report a robust procedure for cannabinoid self-administration. Conflicting results have also been reported in the literature with the conditioned place preference paradigm with various cannabinoids producing either preference or aversion depending on the specific methodological design. Likewise, cannabinoids do not share with other drugs of abuse the potential to produce clear and robust behav- 10 μg/5 μl, ICV DA [275] ioral sensitization. Overall, experimental data using the above mentioned paradigms suggest that the experimental conditions required revealing cannabinoid-reinforcing properties are different from those used with other classical drugs of abuse.
Although many cannabinoids are found in cannabis sativa preparations, maybe only 9 -THC is really abused by humans. However, cannabis is more than simply 9 -THC. Indeed, cannabis preparations contain several cannabinoid and noncannabinoid compounds, which may contribute to the behavioral effects of cannabis in humans. After all, however, the pleasurable effects of cannabis preparations in humans appear to be in disagreement with preclinical experimental studies. Nevertheless, most preclinical studies utilize 9 -THC or other synthetic cannabinoid agonists that stimulate cannabinoid receptors. Several other reasons might also explain this difference. There may be significant species differences in functions of the cannabinoid system in animals and humans. Perhaps the recreational use of cannabis by humans reflects more complex sensory and cognitive effects that cannot be experienced by lower animals. This may, also, explain why cannabinoids do not induce the typical pattern of obsessive drug-seeking and compulsive drug-taking behavior, observed in humans addicted to other, more typical drugs of abuse, such as cocaine, heroin, alcohol and nicotine. Pharmacokinetic factors (i.e. factors related to bioavailability of the drug formulation used, lipophilicity, distribution and storage in fat tissue, metabolism and elimination rate) seem to be responsible in part for the subjective effects of cannabinoids. Thus, the possibility still remains, that the abuse of cannabinoids by humans is related to a rewarding action which could be difficult to reveal in the currently used animals models as a consequence of the long duration and slow elimination action of cannabinoid drugs or other unknown factors. Unequivocally, however, preclinical experimental studies utilizing the above mentioned behavioral models have provided a better understanding of the neurobiological mechanisms involved in exogenous and endogenous cannabinoids functions and have revealed some commonalities between cannabinoids and typical drugs of abuse. On the other hand, studies using the drug discrimination paradigm have shown subjective effects of cannabinoid drugs, that are specific to this group and in general do not generalize to other drugs of abuse. However, we do not know yet the characteristics and the significance of those subjective effects. Interestingly, similarly with other drugs of abuse, chronic treatment with cannabinoids leads to the development of tolerance to most of their pharmacological effects which probably relates with adaptive changes in the endocannabinoid system accompanied by CB 1 receptors down-regulation and attenuation of G-protein activation. However, there is no conclusive evidence for a robust spontaneous withdrawal in experimental animals treated chronically with cannabinoids. Cannabinoid agonists seem to increase dopamine release in the nucleus accumbens under certain experimental conditions, a neurochemical marker shared with traditional drugs of abuse. However, critical details of the conditions under which this neurochemical effect is effectuated in relation to the physiology of the cannabinoid system remain to be revealed. In the near future, the explosion of research in the field of cannabinoids and the discovery of optimal pharmacological tools will most certainly also provide insights into the physiological role of the endogenous cannabinoid system in brain reward and in habitual adaptive function.
Key Learning Objectives:
1. Despite the clinical evidence that cannabis derivatives produce clear subjective motivational responses in humans leading to drugseeking behavior and in a specific proportion in repeated drug use, the reinforcing/rewarding attributes of these subjective effects are difficult to define in experimental animals.
2. The majority of the studies using the intracranial self-stimulation paradigm failed to show any reward facilitating effects for 9 -THC or other cannabinoids, or on the contrary, they present data for anhedonic actions of these compounds, at least in the high dose range.
3. Most attempts to obtain a robust self-administration of 9 -THC or other synthetic cannabinoids, under standard experimental conditions, have been negative. However, several recent studies demonstrate that canabinoids can initiate and sustain active selfadministration in experimental animals, although the range of conditions under which this occurs is more limited than with typical drugs of abuse.
4. There is limited evidence that 9 -THC or other cannabinoids can induce the development of conditioned place preference in rodents under certain experimental conditions. 5. Drug discrimination studies have shown subjective effects of cannabinoid drugs, that are specific to this group and in general do not generalize to other drugs of abuse. Thus, the discriminative effects of cannabinoids appear to be neurobiologically distinct involving most likely other neuronal circuits than those participating in the discriminative effects of classical drugs of abuse.
6. Cannabinoids do not share with other drugs of abuse the potential to produce clear and robust behavioral sensitization.
7. Chronic treatment with cannabinoids leads to the development of tolerance to most of their pharmacological effects. However, there is no conclusive evidence for a robust spontaneous withdrawal in experimental animals treated chronically with cannabinoids.
8. Cannabinoid agonists increase dopamine release in the nucleus accumbens of experimental animals under certain experimental conditions.
9. All the above illustrate the differential status of cannabinoids as atypical drugs of dependence and abuse.
Future Research Questions:
1. The available animal models for measuring the potential reinforcing/rewarding effects of cannabinoids together with the availability of new and more selective compounds that act on the cannabinoid system provide exciting opportunities to search for drugs that possess the therapeutic potential attributed to cannabis and 9 -THC, but lack the undesirable psychotropic effect of dependence and abuse liability.
2. Careful scrutiny of the commonalities and differences in the reinforcing/rewarding properties of cannabinoids and other drugs of abuse should provide a better understanding of the subtle but different neurobiological mechanisms underlying their abuse potential.
3. A multidisciplinary approach examining molecular and cellular changes in conjunction with animal models for studying reinforcing and dependence-producing properties of cannabinoids will undoubtedly further our current understanding.
4. The neurobiological underpinnings and the physiological consequences of the stimulatory effects of cannabinoids and endocannabinoid neurotransmission modifiers on dopamine release in the nucleus accumbens, in particular in relation to their pertinent motivational and dependence-producing actions, remain a subject of active research.
5. Detailed research into cannabinoid actions may help to elucidate not only the relevant actions of cannabinoid drugs, but also the role of the endogenous cannabinoid system in brain reward.
